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Summary.-One hundred and seven untreated patients with acute myelogenous
leukaemia (AML) were admitted to St Bartholomew's Hospital between 10 October
1970 and 31 January 1973. Before receiving drugs to induce remission they were
allocated alternatively into 2 groups to decide their remission treatment-a group
to receive chemotherapy alone and a group to receive the same chemotherapy with
immunotherapy. The patients were then given induction chemotherapy and 45
of them attained complete remission. All patients in remission then received
chemotherapy consisting of 5 days treatment every 28 days. Patients receiving
immunotherapy were also given multiple weekly intradermal injections of irradiated
stored AML cells and Glaxo B.C.G. using a Heaf gun. There were 19 patients in
the group which received only chemotherapy during remission; 7 of these patients
remain alive (median survival after attaining remission 303 days) and only 5 are
still in their first remission (median remission length 188 days). Twenty-three
patients were allocated to receive immunotherapy during remission in addition to
chemotherapy and 16 remain alive (median 545 days) and 8 are in their first remission
(median 312 days). The difference in survival of the two groups is significant with
a P value of 0 003.
FOLLOWING recent improvements in
chemotherapy, approximately half of all
patients with acute myelogenous leuk-
aemia (AML) achieve complete remission
(Crowther et al., 1970; Crowther et al.,
1973) but chemotherapy alone has proved
disappointing for maintaining these re-
missions (Clarkson, 1972; Whitecar et
al., 1972; Crowther et al., 1973). This
study was undertaken to see if remission
length and survival could be increased
when immunotherapy was included as
part of the remission treatment. In a
clinical study of patients with AML,
chemotherapy alone during remission has
been compared with chemotherapy plus
immunotherapy. The maintenance che-
motherapy was chosen to avoid immuno-
suppression as far as possible. Labora-
26
tory studies showed (vide infra) that this
could be achieved by giving the cytotoxic
drugs in widely spaced courses of short
duration and by avoiding the use of
powerfully immunosuppressive agents
such as cyclophosphamide. The immuno-
therapy given was irradiated allogeneic
stored myeloblastic leukaemia cells and
B.C.G.; the reason for choosing this
combination for immunotherapy and the
doses and timing employed are outlined
below.
Scientific basis for the immunotherapy
regitme
Attempts to influence the course of
cancer in man by a variety of different
immunological manoeuvres have been
reported for more than 80 years (seeR. L. POWLES ET AL.
review by Currie, 1972). To show that
these procedures are clinically useful
requires comparative studies and up till
now only 4 have been reported, 3 of
acute lymphoblastic leukaemia (Mathe,
1969; Medical Research Council Child-
hood Leukaemia Study Group Report,
1971; Leukaemia Study Group A (U.S.),
1973), and the fourth in patients with
gliomata (Bloom et al., 1973).
The immunotherapy regimen described
here is based on results obtained from
animal experiments and from clinical
studies in which changes in the immuno-
logical responses of patients with acute
leukaemiaweremeasuredafter auto-immu-
nization With irradiated leukaemia cells.
An ahti-tumour action of injected
irradiated tumour cells in animals was
demonstrated by Haddow and Alexander
in 1964, who found that the rate of
recurrence of primary chemically induced
sarcomata in rats following limited local
radiotherapy was reduced by the injec-
tion of autologous tumour tissue obtained
by biopsy and rendered non-viable by
irradiation in vitro. In the absence oflocal
irradiation of the tumour, the immuno-
therapy was ineffective because the host's
immune reaction can kill only a small
number of residual tumour cells even
after stimulation. Later studies (Alexan-
der et al., 1967) showed that autoim-
munization overcame an immunological
defect in the tumour bearing rat. The
immune responses against primary sarco-
mata in unimmunized rats is impaired
because the lymph nodes draining the
tumour are paralysed by antigen over-
load. However, a powerful systemic im-
mune response can be generated in
tumour bearing rats by inoculation of
irradiated tumour cells, at sites distant
from the tumour, since lymph nodes
that are not paralysed are stimulated in
this way.
The response seen in rats with primary
sarcomata prompted a clinical trial in
1964 of patients with glioma muLlti-
formae, but no benefit was obtained
from giving irradiated autologous tumour
following surgeryandradiotherapy (Bloom
et at., 1973). We now think that the
reasons for this failure were the anatomical
inaccessibility of the tumour and insuffi-
cient immunization.
Quantity and frequency of treatment.-
In studies on patients with dissemin-
ated melanoma immunization with irradi-
ated tumour cells induced the appearance
of antibodies directed against the tumour
but this phenomenon was only seen
after more than 5 x 108irradiated tumour
cells had been injected (Ikonopisov
et al., 1970). The effect was only
transient and the antibodies d(lisappeared
within 2 weeks of autoimmunization.
The same effect could be obtained
repeatedly when sufficient tumour was
availableforfurtherimmunizations. Auto-
immunization with similar quantities of
tumour also temporarily increased the
specific cytotoxicity of the mononuclear
cells in the blood of these patients (Currie,
Lejeune and Hamilton Fairley, 1971;
Currie and Basham, 1972).
Before the present leukaemia trial
was started, we determined the response
of leukaemia patients in remission to
immunization with irradiated leukaemia
cells (Powles et al., 1971). This was
done by measuring the change in the
extent to which their blood lymphocytes
transformed when cultured with stored
autologous leukaemia cells which had
been collected before the induction of
remission with chemotherapy. Immuni-
zation with 1 x 109 irradiated leukaemia
cells was required to increase transiently
the reactivity of the patients to the
antigens on the leukaemia cells and
recent studies by Gutterman et al. (1973)
confirm this effect. These findings sug-
gested that the frequent inoculation of
1 X 108 to 1 x 109 irradiated tumour
cells may be needed to obtain a therapeutic
effect. This meant that a major problem
was to obtain sufficient tumour cells for
immunization.
By using the I.B.M. blood cell separa-
tor this became possible in adult patients
with AML. With thismachine more than
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1 X 1012 leukaemia cells can be col-
lected from patients presenting with a
high peripheral blast count and these
cells can be frozen and stored in a viable
state in liquid nitrogen (Powles and
Grant, 1973). We decided that a total
of 1 x 109 irradiated leukaemia cells
should be administered weekly at multiple
subcutaneous states.
The reasons for using allogeneic cells.
The leukaemia cells used for immuniza-
tion were obtained from other patients
with the same disease (i.e. allogeneic).
Using the patient's own stored cells
would have severely limited the number
of patients who could enter the trial,
since less than a quarter of presenting
patients had enough circulating leukaemia
cells, or were well enough to make col-
lection with the I.B.M. machine feasible.
Animal experiments had already shown
that the production of both antibodies
(Gorer and Amos, 1956) and cytotoxic
lymphocytes (Alexander and Hall, 1970)
directed against weak tumour antigens
was more effective following immuniza-
tion with allogeneic than with syngeneic
tumour cells. The use of allogeneic
leukaemia cells in man constituted a
calculated risk since the evidence that
leukaemia associated antigen(s) is common
to all patients is tenuous. The technique
of mixed cell cultures which demonstrated
the presence of a specific antigen on acute
leukaemia cells (Fridman and Kourilsky,
1969; A?iza et al., 1969; Powles et al.,
1971; Gutterman et al., 1972), cannot
provide information about cross reactivity.
But the serum of patients with leukaemia
frequently contains factors which alter
the reactivity of these mixed cell cultures
(Alexander and Powles, 1973; Gutterman
et al., 1973) and in some instances we have
found these factorsspecifically inhibitleuk-
aemia cell recognition with cross reactivity
between patients (unpublished). Herber-
man (1973) found that delayed hypersensi-
tivity skin reactions could be induced in
patientswithacute myelogenousleukaemia
by extracts ofallogeneic AML cells. These
data suggestthat amembrane antigen may
be shared by leukaemia cells taken from
different patients. The assumption for
a cross reacting antigen in myelogenous
leukaemia is strengthened by the demon-
stration (Hellstr6m et al., 1971; Currie
and Basham, 1972) that solid tumours of
the same histological type have common
tumour specific antigens.
The use ofB.C.G. While webelievethe
important component of the immuno-
therapy tested in this study was irradiated
AML cells, we also decided to give
weekly B.C.G. The reason for doing
this follows the finding first made by
Halpern et al. (1959), and then widely
confirmed, that in animals B.C.G. stimu-
lated immune reactivity in a nonspecific
way and increased the animal's capacity
to resist a subsequent challenge with
bacteria or tumour. This effect is weaker
and occurs less frequently when B.C.G.
is given to animals already bearing
tumours (i.e. therapy as opposed to
prophylaxis (Old et al., 1961; Haddow
and Alexander, 1964; Mathe, Pouillart
and Lapeyraque, 1969; Parr, 1972) but
when given with tumour cells an aug-
mented effect may be obtained. At
present there are no laboratory data
which indicate that B.C.G. as administered
in this trial (i.e. Glaxo B.C.G. given with
amultipuncture Heafgun (EschmannBros.
and Walsh Ltd)) influences the reactivity
of man to the tumour, nor did B.C.G.
influence the length of remission in
acute lymphoblastic leukaemia (ALL) in
trials conducted both by the Medical
Research Council in Britain (1971 ) and the
Children's Cancer Study Group A in the
United States (1973).
The only clinical evidence that B.C.G.
may be useful therapeutically is based
on the study by Mathe (1969) for main-
taining remission in childhood acute
lymphoblastic leukaemia (ALL) using
either B.C.G. alone or in conjunction
vwith irradiated leukaemia cells.
The reason for selecting acute myelo-
genous leukaemia.-We decided to con-
duct our studies in AML, not ALL, because
modern chemotherapy is so poor for
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controlling the former that an answer
soon becomes apparent, whereas many
years of study are required to obtain
significant results in ALL. In addition,
patients with AML are adults and so
tolerate better painful intradermal injec-
tions of cells which we give weekly.
More recently we have found (unpub-
lished) that patients with AML might
be better suited for immunotherapy than
patients with ALL because during remis-
sion lymphocytes from patients with AML
respond better in the mixed lymphocyte
reaction than those ofpatients with ALL.
PATIENTS AND METHODS
All patients with AML who were first seen
at St Bartholomew's Hospital between 10
August 1970 and 31 January 1973 were
included in the study. Analysis was made
of the data completed to 31 May 1973.
Before any treatment was given to induce
remission, all patients were allocated into
one of 2 groups on an alternate basis to
determine whether they would receive im-
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munotherapy ifthey achieved remission. This
was not a random selection. The total entry
of new patients was 107; 54 of these were
included in the series described by Crowther
et at. (1973) and the rest represent patients
seen subsequently. The induction protocol
ofdrugs (Fig. 1) consisted ofdaunorubicin and
cytosine arabinoside, given in 3 slightly
modified ways (Studies 2, 3 and 4). Forty-
five patients passed into full remission so that
the overall remission rate for the 3 trials now
stands at 42%. (Study 2-7 of 22 patients;
Study 3, now complete-23 of 54 patients;
Study 4, which still takes new patients-15 of
31 patients.) A few patients did not pass
into complete remission after more than 5
months of treatment but are still alive. It
now seems unlikely that they will achieve
remission and in this analysis have been
counted'astherapyfailures. Age is themajor
influence on remission rate, the figure for
patients under 30 years of age being 59%
(13 of 22); for 30-44 years of age, 55% (12 of
22); 45-59 years of age, 41% (16 of 39); 60
years of age and over, 17% (4 of24).
All patients inremission (Table I) received
identical maintenance chemotherapy (Fig. 1)
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FIG. 1. Squares containing D.C.tI: cytosine arabinoside i.v. injection 8-hourly x 6. Total dose
in 48 hours 4 mg/kg. No treatrment then for 72 hours. Then cytosine arabinoside 2 mg/kg i.v.
injection daily for 3 days and daunorubicin 1-5 mg/kg i.v. fast infusion on the first of these 3 days.
Squares containing D.C.: cytosine arabinoside 2 mg/kg i.v. daily for 5 days with daunorubicin
1 5 mg/kg i.v. on the first of these days. Squares containing T.C.: cytosine arabinoside 2 mg/kg
i.v. daily and 6-thioguanine 2 mg/kg orally daily, both for 5 days concurrently. Vertical arrows:
Immunotherapy consisting of weekly (a) Glaxo B.C.G. 1 X 106 live organisms percutaneously
given using a multipuncture Heaf gun (40 punctures) and (b) irradiated allogeneic myelogenous
leukaemia cells, 1 x 109 intradermally and subcutaneously at three sites. Bart's 4 trial differs
from Bart's 3 trial in excluding all patients over 60 years of age.
L.--
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consisting of 5-day courses of cytosine
arabinoside and daunorubicin, alternating
with 5 days of cytosine arabinoside and
6-thioguanine. Between every 5 days of
treatment there was a 23-day gap and itwas
during this period that those patients allo-
cated received additionalimmunotherapy. All
patients stopped maintenance chemotherapy
after one year (12 courses) and thereafter the
immunotherapy patients received only im-
munotherapy, and the chemotherapy patients
received no further treatment. The final
allocation of the patients who attained full
remission was 19 to chemotherapy only, and
26 patients to chemotherapy plus immuno-
therapy. These 2 groups did not have equal
numbers because they were allocated when
they first entered hospital and the number in
each group that attained remission was not
the same.
The exact time at which immunotherapy
started(show-nin. Fig1),waswheneverpossible,
just before complete remission, at a time
whenthe marrowwashypoplastic, andinallin-
stances subsequent marrow biopsies confirmed
that these patients achieved a full remission.
Of the 26 patients allocated immuno-
therapy,3have not beenincludedin the analy-
sis. One ofthese patients died ofinfection after
attaining full remission but before immuno-
therapy was given; the other 2 patients are
the most recent entries and we feel have been
in remission for too short a period to make
analysis meaningful (8 days and 22 days)-
see Table I, patients 24, 25 and 26.
Immunotherapy. As soon as the bone
marrow became hypoplastic (i.e. just before
full remission) all immunotherapy patients
received weekly B.C.G. and irradiated allo-
geneic myeloblastic leukaemia cells. The
injections were deliberately timed to avoid
the 5-day courses of chemotherapy.
B.C.G.-The B.C.G. given was a freeze-
dried percutaneous preparation obtained from
Glaxo and when reconstituted contained 10
mg of organisms per ml, of which approxi-
mately 20%0 were viable. Forty needle
punctures in the skin to a depth of2 mm using
a Heaf gun gave an approximate dose of
1 x 106 live organisms. All four limbs
received the B.C.G. in turn, one weekly.
Cells. The cells used for immunotherapy
were irradiated AML cells and were injected
into the 3 limbs not receiving the B.C.G. that
w-eek. These cells were collected from the peri-
pheral blood of suitable patients with AML
using aNCI/IBMcell separator (Buckner etal.,
1969).Useful quantitiesofcells couldbeobtain-
ed from donors with blast counts as low as
1000/mm3 and as many as 1 x 1012 cells
could conveniently be collected from a single
donor ifthe white cell count ofblood was very
high. We have now collected leukaemia cells
from 73 patients between the ages of 8 and 73
yearsandtheysufferedlittlediscomfortduring
the 2-5 hours required to remove the cells.
The leukaemia cells were collected into 70 ml
acid citrate dextrose (Fenwal Formula A) to
give a final cell concentration between
2 x 107 and 1 x 109, depending upon the
blood count ofthe patient. The final volume
of cells was approximately 500 ml (including
the A.C.D.) and the quantity ofplasma varied
according to the cell concentration. If
necessary, the cells were further concentrated
using an MSE 6L centrifuge (2000 rev/min)
for 15 min so as to give a final concentration
of 1 x 109 cells/ml. The red cell concentra-
tion varied between 1 x 108/ml and 1 x 109/
ml. The cell suspension was then mixed with
an equal volume of culture medium 199
(Wellcome) containing dimethylsulphoxide
(DMSO) and dispensed into 2 ml glass
ampoules which were heat sealed. The final
concentration of DMSO was 10%. The cells
were then frozen slowly at 1°/min to - 30°C
using a Planer Ltd. gas phase programmed
freezer and stored in the gas phase liquid
nitrogen. When required the cells were
thawed rapidly at 37°C, washed and resus-
pended in medium 199 at 4°C. This process
was found to damage only a small fraction of
the cells (Powles and Grant, 1973). The cells
were then irradiated at 4°C at a concentration
of 1 x 108/ml with 10,000 rad at a rate of
1000 rad/min using a cobalt 60 source, and
then immediately injected into the 3 limbs,
both intradermally and subcutaneously.
Approximately 1 x 109 cells suspended in
6 ml of culture medium were injected each
week at 3 sites (i.e. 2 ml into each site).
Individual patients received cells from the
same donor for as long as possible. These cells
wereselectedformorphological similarity with
the recipient's disease, but no attempt was
made to match either the red blood cell or
transplantation antigens ofthe donor and the
recipient. If patients relapsed the initial
induction treatment with daunorubicin and
cytosine arabinoside was repeated whenever
possible. If no regression of the leukaemia
was seen the treatment was usually changed
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to a combination of cyclophosphamide and
6-thioguanine. Ifremission occurred then the
maintenancetreatmentwas modifiedtoasingle
injection of daunorubicin and 3 days of cyto-
sine arabinoside, followed 11 days later by 3
days of oral cyclophosphamide and 6-thio-
guanine. After another 1l-day gap, the whole
cycle was repeated with maintenance chemo-
therapy for 3 days every fortnight. Those
patients who previously received immuno-
therapy were given further treatment with
B.C.G. and a different population of
irradiated AML cells.
RESULTS
The age, sex, initial blood count and
morphological sub-type of the patients
studied are shown in Table I. Also
included in this table are the remission
lengths and survival times of these
patients.
Survival time
Twelve of the 19 patients receiving
only chemotherapy for the maintenance
of remission have died, compared with
only 7 of the 23 immunotherapy patients.
Fig. 2 shows actuarial analysis of the
duration of survival of these patients
after remission induction (given in Table
I) and allows the prediction that the
median duration of survival of the
chemotherapy group is 303 days and 545
days for the immunotherapy group (in
fact, this group of patients has not quite
reached the median yet). The mean
duration required to obtain remission in
these patients is 60 days and this should
be added to above figures to obtain
overall survival time after diagnosis.
Statistical analysis of the survival data
(Table II, column 5) shows a significant
TABLE II. Statistical Analysis of Duration of First Remission and Survival
Remission length
Trial
Analysis (late
Data date*
N
0
E
O/E
C
C+I
C+I C
C 1-I
C+I
C
C+I
R.R.
p
Remissionl C
median (days) C+I
Survival C
median (days) C+I
1
2.3.4
31.1. 73
31.1. 73
18
20
13
9
(11)
7 -41
14-59
(16 - 59)
1 -75
0-62
2 -84
0 02
188
375
2
2.3.4
31.5.73
31.5. 73
19
23
14
12
(15)
9-52
16-48
(19-48)
1 -47
0 73
2 -02
0-10
188
312
3 4
2+3 2.3.4-
31.5.73 31.5.7
20.11.72 31.5.7
15
15
12
8
7 -22
12-78
1 -66
0-63
2-65
0 04
209
371
14
16
9
7
5 02
10-98
(13 - 98
1 -79
0-64
2 -81
0 05
Survival
5
t 2.3.4
'3 31.5.73
'3 31.5.73
19
23
12
5
(7)
5-88
11-12
(13- 12)
I 2 -204
0 45
4-54
0 003
3031
545
* Patients admitted to trial up to this time.
± Analysis of patients who have been at least 3 months in remission.
t Survival calculated from the time they enter complete remission.
C Chemotherapy only group; C + I = Chemotherapy plus immonotherapy; N = Number of patients
in each group; 0 = Observed number of patients relapsing/deaths; E = Expected number of patients
relapsing/deaths, calculated by the " Logrank " non-parametric method (Mantel, 1966; Cox, 1972; Peto
and Peto, 1972); O/E = Relative relapse rate; P = Statistical significance level of results; R.R. measures
the ratio of relative relapse rate in Group C compared with C + I. Brackets: Columns 0 and E = actual
number of relapses in immunotherapy group as opposed to the number of relapses that occurred up to the
time the last relapse occurred in chemotherapy group.
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SURVIVAL AFTER REMISSION INDUCTION.
918
SURVIVAL AFTER REMISSION INDUCTION (in days)
FIG. 2. Survival following remission of two groups of patients with AML (Barts. 2, 3 and 4) allo-
cated at presentation; one group received maintenance chemotherapy alone, the other group
chemotherapy plus immunotherapy. The percentage surviving at different times has been
calculated by standard actuarial methods. Each dot represents a patient still living, and vertical
drops show the time at which individual patients died. Twelve of the 19 chemotherapy alone
patients and 7 of the 23 chemotherapy plus immunotherapy patients have died. Analysis of
follow-up to 31 May 1973 ofpatients admitted to the study up to 31 May 1973.
REMISSION DURATION
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FIG. 3.--Similar analysis to Fig. 2 of the duiration of first remission of the same patients showni in
Fig. 2. Fourteen of the 19 chemotherapy alone patients and 15 of the 23 chemotherapy plus
immimotherapy patients have relapsed.
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difference between the two groups (P -
0.003).
Remission length
Fourteen of the 19 patients in the
chemotherapy only group have relapsed
compared with 15 ofthe 23 chemotherapy
plus immunotherapy patients. Actuarial
analysis (Fig. 3) predicts a median re-
mission length for the chemotherapy
group of 188 days compared with 312
days for the immunotherapy patients.
These remission figures are not as good
aswehavepreviouslynoticed and reported
(Powles etal., 1973; Powles, 1973). Analy-
sis of the data in January 1973 (Table II
column 1) showed the median remission
length of the chemotherapy patients
was doubled by the inclusion of immuno-
therapy from 188 to 375 days (the rela-
tive relapse rate of the chemotherapy
patients was 2-84 times that of the
immunotherapy patients: P - 0'02). Ana-
lysis of the present data (column 2)
shows that the median remission length
for the chemotherapy group is unchanged
but the median duration for the immuno-
therapy patients is reduced to 312 days,
with a relative relapse rate of only 2-02
times (P = 0.10). The difference between
the January and May figures is due to
those patientswho have entered the trial in
the last 6 months and who have been
relapsing quickly. This is shown by
new analysis of patients admitted up to
November 1972 (Table II) which excludes
the recent admissions (column 3) or
patients relapsing in less than 3 months
(column 4) and shows a relative relapse
rate, at least 2-65 times greater for the
chemotherapy patients (P =0.04). Not
only have the remission lengths been short
for patients recently admitted to the
trial but we have had fewer patients
going into complete remission (see page
372). Essentiallythere isno difference bet-
ween the proportion of patients relapsing
early in the two groups but a significant
difference for those still in remission after
120 days (Fig. 3).
The influence of age on the duration of
remission
The age of the patients does not
influence the length of remission in this
study. The 4patients over 60 years of age
(by chance all allocated to the chemother-
apygroup) have donewell, only one relaps-
ing and dying in less than the expected
median for this group (Table I).
Second remissions
Four of the 15 relapsed patients in
the immunotherapy group were reinduced
into a full second remission using chemo-
therapy (Table I) and then continued
on modified chemotherapy plus immuno-
therapy. In the chemotherapy group
only one of the 19 patients in relapse
achieved a second remission.
Local effects of immunotherapy
The B.C.G. injections produced an
area of erythema which appeared at the
site of the needle marks after about 24
hours and became vesicular during the
following few days. A crusting lesion
about 1 cm across then persisted for
about 3 months and usually healed
leaving a faint scar. Often the local
lymph nodes were enlarged between one
and 3 weeks after the injection. During
the first 3 weeks after completing induc-
tion chemotherapy there was no local
reaction to B.C.G. but thereafter all
sites, including those previously inocu-
lated, became inflamed. There was no
evidence of a systemic effect of B.C.G. in
post-mortem studies on 2 patients in
this series who had received immuno-
therapy, although both had been treated
for many months.
The injections of allogeneic cells,
although painful, produce no local lesions
other than an immediate oedematous
response and in no instance did we see a
delayed type hypersensitivity reaction.
Immune status
After the induction treatment the
mixed lymphocyte reaction (MLR) of
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TABLE III.-One Way Mixed Lymphocyte Reactions (MLR)* of Normal Donors and
AML Patients in Remission
Mixed lymphocyte
reaction of normal donors ,5~~~
No.
Month observed
9/70 36
10/70 80
11/70 51
12/70 56
1/71 41
2/71 44
3/71 51
4/71 32
5/71 48
6/71 47
7/71 40
8/71 48
9/71 36
Mean
20979
18750
18887
18520
19523
19404
18639
18438
20562
18945
17771
18130
18188
S.D.
4151
5012
2343
3490
4269
2598
1483
1535
4290
2060
3168
2828
1319
S.E.
of
mean
691
560
728
466
666
391
207
271
619
300
501
408
219
Mixed autologous
lymphocytes only
(-ve controls)
t A .A
No.
observed
36
66
52
56
41
44
52
32
48
48
40
48
36
Mean
562
514
483
465
493
471
449
431
369
362
387
368
369
S.D.
478
214
88
89
151
39
60
104
103
120
111
53
46
S.E.
of
mean
79
26
12
12
23
5
8
18
14
17
17
7
7
AML patientst remission
lymphocytes stimulated with
mitomycin treated normal lympho-
cytes
S.E.
t No. of
Month observed Mean S.D. mean
1
2
3
4
5
6
7
8
9
10
11
12
13
36
38
42
32
30
20
14
16
18
26
14
6
11
4409
5833
6359
8158
6978
7957
7891
7331
6451
7680
8767
7862
9302
4163
3655
4330
3407
3598
4984
3240
3526
4340
3466
1504
3217
2022
693
593
668
602
657
1114
865
881
1023
679
402
1313
609
* For all cultures one million reacting lymphocytes were suspended in 1 ml of culture medium 199 con-
taining 12-5% foetal bovine serum (FBS). For mixed lymphocyte reactions 0 5 x 106 stimulating normal
allogeneic lymphocytes were treated with 25 mg/ml-' of mitomycin C, washed and suspended in 2 ml
medium 199 and 12-5% FBS and added to the reacting lymphocytes. In these conditions the stimulating
lymphocytes cannot themselves synthesize DNA. These cell suspensions were then cultured in sealed
tubes at 37°C for 6 days. DNA synthesis in the cultured reacting lymphocytes was determined by measuring
the incorporation of radioactive thymidine. 15 Ci of [3H] thymidine (specific activity 15 Ci mmol/l) was
added and after 60 min at 37°C the cells were extracted by filtration on to a Millipore filter. The cells on the
filter were exposed to 10% ice-cold trichloracetic acid, washed with ethanol and radioactivity was determined
by liquid scintillation counting. Thymidine incorporation was expressed as ct/min. In cultures in which
there was no stimulation (one way autologous mixed lymphocyte reactions) in both normal donors and the
AML patients studied, the ct/min was always less than 1000 and so in allogeneic one way MLRs values
greater than 1000 were regarded as a significant stimulation.
t Results obtained from 14 patients receiving maintenance treatment of immunotherapy plus chemo-
therapy (see text).
$ Consecutive 28-day periods after the cessation of induction chemotherapy. (Not all patients were
tested every month.)
the AML patients was severely depressed.
During remission and in spite of receiving
intermittent chemotherapy the MLR in
these patients becomes steadily more
reactive (Table III). However, a notable
feature was that individuals showed
marked day-to-day variability in the
MLR, particularly following the induction
of remission. There was no detectable de-
pression of the MLR as an immediate
consequence of the 5-day courses of main-
tenance chemotherapy.
Studies of the immune status of our
immunotherapy patients are to be re-
ported more fully in a later publication,
but it is of interest to note that we have
seen no consistent alteration in the skin
reactivity to B.C.G. or the mixed lympho-
cyte reaction before relapse in these
patients.
DISCUSSION
It is not possible to compare directly
the present study with that of Mathe
(1969) in ALL since both the disease he
treated and the immunotherapy he gave
were different. In his study patients
received B.C.G., cells, or B.C.G. as well
as cells, and after about one year those
patients who had received B.C.G. alone
began to receive cells. Also, the number
of leukaemia cells Mathe gave was 10,000
times less than that used in this study
and he used a different strain of B.C.G.
Our study shows that immunotherapy, as
we give it, has a significant beneficial
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effect on the duration ofremission and the
length of survival of patients with AML,
but the placeofimmunotherapy for treat-
ing malignant disease must always be
considered inthe lightofthe best available
conventional methods. The results of two
groups ofinvestigators inthe United States
(Whitecar etal., 1972; Clarkson, 1972) using
intensive chemotherapy for treating AML
during remission are very encouraging but
as yet it is uncertain whether they will be
better or worse than our immunotherapy
group and so we feel justified in con-
tinuing this method of treatment. But
patients in our immunotherapy group
still relapse and die. Although both
remission length and survival are nearly
doubled, the likelihood of cure in any
but a few of these patients seems remote.
To improve these results it is essential
to measure the specific host response to
immunization in an attempt to develop
a rationale for better methods ofimmuno-
logical treatment. It is for this reason
that we use leukaemia cells from a single
donor instead of using a pool of cells.
We can then measure host cell mediated
and humoral cytotoxicity directed against
both the cells used for immunizing and
the patient's own stored leukaemia cells
(if available).
We are indebted for support for this
study to the Leukaemia Research Fund,
the Imperial Cancer Research Fund, the
Joseph Frazer Strong Trust and the
Medical Research Council. We would
like to thank Sir Ronald Bodley Scott
and Drs P. E. Thompson Hancock and
H. E. M. Kay for their advice and en-
couragement in this study.
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